An HPK1 inhibitor enhanced the tumour response to anti-PD-1 immunotherapy in non-Hodgkin’s lymphoma
Authors:
- 27 April 2023
- journal article
- research article
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 23 (7) , 3767-3780
Abstract
Anti-PD-1 immunotherapy has been widely applied in patients with some types of lymphoma. Classical Hodgkin’s lymphoma (cHL) is highly sensitive to immunotherapy, but non-Hodgkin’s lymphoma (NHL) does not show a good response. Studies have indicated that haematopoietic progenitor kinase 1 (HPK1) suppresses T cells and reduces antitumour immunity. Therefore, HPK1 inhibitors may restore and elicit antitumour immune responses and are promising candidate drug targets for cancer immunotherapy. We first explored the Gene Expression Profile Interactive Analysis (GEPIA) database and predicted that HPK1 expression was increased in diffuse large B-cell lymphoma (DLBCL) and associated with Nod-like receptor protein 3 (NLRP3) expression. We investigated whether an HPK1 inhibitor could enhance the tumour response to anti-PD-1 immunotherapy in NHL and the association between HPK1 and NLRP3 expression. Employing shHPK1 and an inhibitor, we demonstrated that the HPK1 inhibitor increased anti-PD-1-mediated T-cell cytotoxicity in BJAB and WSU-DLCL2 cells cocultured with peripheral blood mononuclear cells (PBMCs). HPK1 inhibitor treatment increased PD-1, PD-L1, Bax, p53 and NK-kB expression but decreased NLRP3 expression, indicating that the HPK1 inhibitor promoted apoptosis and blocked the NLRP3 inflammasome pathway to affect anti-PD-1-mediated T-cell cytotoxicity. Moreover, the HPK1 inhibitor enhanced the efficiency of anti-PD-1 immunotherapy in vivo in a zebrafish xenograft model of NHL. In summary, this study provides evidence that an HPK1 inhibitor enhanced the tumour response to anti-PD-1 immunotherapy in NHL by promoting apoptosis and blocking the NLRP3 pathway. These findings provide a potential therapeutic option for NHL combining HPK1 inhibitor treatment and anti-PD-1 immunotherapy.Keywords
Funding Information
- Natural Science Foundation of Fujian Province (2020J011117)
- Joint Funds for the Innovation of Science and Technology (2019Y9040)
- Fujian Provincial Health Technology Project (2022CXA027)
This publication has 24 references indexed in Scilit:
- The Kinase Activity of Hematopoietic Progenitor Kinase 1 Is Essential for the Regulation of T Cell FunctionCell Reports, 2018
- PD-1 expression and clinical PD-1 blockade in B-cell lymphomasBlood, 2018
- The diverse functions of the PD1 inhibitory pathwayNature Reviews Immunology, 2017
- The future of cancer treatment: immunomodulation, CARs and combination immunotherapyNature Reviews Clinical Oncology, 2016
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's LymphomaNew England Journal of Medicine, 2015
- PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated MalignanciesClinical Cancer Research, 2013
- Inflammasomes in carcinogenesis and anticancer immune responsesNature Immunology, 2012
- Programmed Death Ligand 1 Is Expressed by Non–Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T CellsClinical Cancer Research, 2011
- The InflammasomesCell, 2010
- Hematopoietic progenitor kinase 1 negatively regulates T cell receptor signaling and T cell–mediated immune responsesNature Immunology, 2006